Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 0.91B P/E 8.03 EPS this Y -151.00% Ern Qtrly Grth -
Income -29.73M Forward P/E -13.13 EPS next Y 108.80% 50D Avg Chg 15.00%
Sales 166.8M PEG - EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 2.75 EPS next 5Y - 52W High Chg -10.00%
Recommedations 2.00 Quick Ratio 3.95 Shares Outstanding 26.92M 52W Low Chg 162.00%
Insider Own 8.75% ROA -11.11% Shares Float 24.55M Beta 2.60
Inst Own 90.48% ROE -10.83% Shares Shorted/Prior 4.61M/4.21M Price 34.14
Gross Margin 91.04% Profit Margin -17.82% Avg. Volume 429,335 Target Price 67.63
Oper. Margin -59.22% Earnings Date May 7 Volume 328,376 Change -2.23%
About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings News
03/28/24 Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
03/22/24 Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...
03/17/24 Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/09/24 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
03/08/24 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
03/08/24 Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call
03/07/24 Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments
03/07/24 Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
03/07/24 Arcturus Therapeutics: Q4 Earnings Snapshot
03/07/24 Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
03/04/24 Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
02/26/24 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
02/26/24 Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
02/22/24 Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
02/21/24 Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
02/20/24 3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
02/20/24 Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
02/05/24 New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
01/23/24 18 High Growth Low PE Stocks
12/21/23 CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
ARCT Chatroom

User Image SouthSideInvest Posted - 3 hours ago

$ARCT wth

User Image wahoowa96 Posted - 13 hours ago

$ARCT ARCT-032 is still hot…Averaged down from 37 to close to 30.

User Image Choice79 Posted - 2 days ago

$ARCT good article today on seeking alpha if you have a membership. Talked about the cf potential and billions in annual revenue if they make it all the way to the market.

User Image Dr_Feel_Good Posted - 2 days ago

$ARCT fantastic rebound today. Top performer in the folio.

User Image 2PacalypseNow4Life Posted - 3 days ago

$ARCT saMRNa platform is worth itself at least 2bn

User Image King316 Posted - 6 days ago

$ARCT As an investor, there are only two days on which it really matters what the stock price is: The day you buy The day you sell If you don’t plan to sell for a long time, the only question that matters is whether it’s a good day to buy more.

User Image EnigmaticFan Posted - 6 days ago

$ARCT RSI hit 30 we’re probably bottoming out for now. Might pick up some shares here, if we go any lower it would be a ridiculous buying opportunity. Some of the people here need to remember that yields have risen dramatically over the last few weeks and were are still a biotech without recurring revenues (for now) although not for much longer. You can’t be thrilled about the company when it’s up and mad at management when the market sells off. There’s nothing fundamental about that, that’s just day trading on emotion. This company is primed to bring in recurring revenue soon, with a transformational first of its kind technology, and they have developed incredible partnerships that are driving products forward. I know what I’m holding and I’m confident about the future of the company which is why the drop in price doesn’t bother me, it’s just a buying opportunity.

User Image ctenidae Posted - 1 week ago

$ARCT I fear a down day today as the market mis-interprets the presentation they gave yesterday on ARCT-810. Oh noes! Patients with no clinical symptoms didn't show changes after a single dose! 15% down today...

User Image Dr_Feel_Good Posted - 1 week ago

$ARCT paying attention to this price level whether we bounce back towards the 200 day at $29.55 or retest just below $25. Prepared to add more if we break below mid range. Looking quite oversold from a technical level.

User Image Stoxdoc Posted - 1 week ago

$ARCT I agree absolutely brutal day

User Image MaxCorona Posted - 1 week ago

$ARCT something not ok. Complete silence, no media articles. Fishy

User Image Choice79 Posted - 1 week ago

$ARCT 8.25% today alone. Ouch. And about 15% this week.

User Image Choice79 Posted - 1 week ago

$ARCT wow. What a crappy two days. Down $5. Somebody is getting out because it’s good volume. I know exciting things are coming but it’s hard to see such a huge drop in a short period of time. We’ve also been talking about all the potential for years. I have to admit, I’m getting tired of talking about the potential. At some point we need to see a higher share price.

User Image King316 Posted - 1 week ago

$ARCT guys relax. You guys know we get OTC and CF data in a few weeks? Also I am sure we get some Information about the results of ARCT 2301 and their commercial targets in Japan. No need for panic

User Image MaxCorona Posted - 1 week ago

$ARCT dear management, obviously you don’t have any results to present and to stabilize the share price. If there should be some buyout offer with a shareprice around 90-100$, we would accept. And maybe this company gets a management, that can present some sales, not only „great pipeline“.

User Image Dr_My Posted - 1 week ago

$ARCT Last 6 weeks been ugly

User Image WaspofWallStreet Posted - 1 week ago

$ARCT ouch may have to see what's happening

User Image Dr_Feel_Good Posted - 1 week ago

$ARCT back on watch here under $30. 👀

User Image King316 Posted - 1 week ago

$ARCT good news from Japan. Another facility from ARCALIS will be build. Arcturus own a part of ARCALIS (I think about 30-40%, not sure about that)

User Image MaxCorona Posted - 1 week ago

$ARCT 2 possibilities: the share price goes up significantly, then the company can stand alone. The price stays on this level or goes a bit lower, then the shareholders will lose patience and the company will get bought. For shareholders both good scenarios.

User Image Night_Owl_Biotech Posted - 1 week ago

We track the share prices of 12 biopharmas that are primarily focused on vaccine therapies. The attachment notes the share prices of the subject 12 since year end. We are only aware of Iscovax that was recently acquired. 11 of the 12 are trading lower year to date. Please let us know if we are missing any biopharmas primarily, again primarily, focused on developing vaccine therapies. We are aware of those with vaccines in their portfolio like AGEN. As always, our data could be wrong. Thank you. $HLVX $PCVX $DVAX $ARCT $NVAX

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/12 $ARCT $BLDE $PSNL

User Image Choice79 Posted - 1 week ago

$ARCT another 57,000 shares added by ark

User Image SouthSideInvest Posted - 1 week ago

$ARCT Added 200 shares here swing

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/11 $ARCT $BLDE $PLTR $PSNL

User Image FlynancialAnalyst Posted - 2 weeks ago

$ARCT +1, Institutions stacking 🐋🧱💸

User Image Wigglyick Posted - 2 weeks ago

$ARCT Watching. I like the rounding bottom. Has seen resistance at the 200wma. Looking for a pullback to 28-29ish area. Good luck

User Image themarker Posted - 2 weeks ago

Cathie Wood and Ark Invest's trade activity from 2024/04/10 $ACHR $ARCT $BLDE $CRSP $NTLA

User Image villabor Posted - 2 weeks ago

$ARCT i have no idea about shares, but: 1. can it perhaps contribute to the valuation if you consider that the current share price is based on the company's very low turnover. is it actually quite good from this point of view? 2. i remember that csl promised arcturus guarantee payments of up to 5 billion dollars, depending on the progress of development and sales? only a very small part of this has happened so far? 3. and perhaps so many insider shares are now being sold in order to push the share price down so that "one" can buy cheaply and then make a real profit? what do you think?

User Image Dr_Feel_Good Posted - 2 weeks ago

$ARCT $DKNG $RTX - top performers today in the folio to cap a wild week on the markets. Going to enjoy some NCAA action and get a good lift in 💪

Analyst Ratings
HC Wainwright & Co. Buy Mar 20, 24
Canaccord Genuity Buy Mar 11, 24
HC Wainwright & Co. Buy Mar 8, 24
Wells Fargo Overweight Mar 8, 24
Citigroup Buy Feb 8, 24
Canaccord Genuity Buy Dec 13, 23
HC Wainwright & Co. Buy Nov 28, 23
HC Wainwright & Co. Buy Nov 15, 23
HC Wainwright & Co. Buy Sep 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chivukula Pad Chief Scientific Off.. Chief Scientific Officer & COO Jul 14 Sell 35.01 25,000 875,250 519,448 07/18/23
Kummerfeld Keith C See Remarks See Remarks Jul 14 Sell 35 6,968 243,880 950 07/18/23
Kummerfeld Keith C See Remarks See Remarks Jul 14 Option 9.38 6,968 65,360 7,918 07/18/23
Chivukula Pad Chief Scientific Off.. Chief Scientific Officer & COO Jul 03 Sell 28.75 5,000 143,750 544,448 07/07/23
Kummerfeld Keith C See Remarks See Remarks Apr 17 Sell 28.18 6,968 196,358 950 04/19/23
Kummerfeld Keith C See Remarks See Remarks Apr 17 Option 9.38 6,968 65,360 7,918 04/19/23
Chivukula Pad Chief Scientific Off.. Chief Scientific Officer & COO Apr 03 Sell 25.38 5,000 126,900 584,448 04/05/23
Chivukula Pad Chief Scientific Off.. Chief Scientific Officer & COO Mar 06 Sell 16.07 5,000 80,350 589,448 03/08/23